Rizatriptan: Difference between revisions
From Pharmacopedia
More actions
| [unchecked revision] | [checked revision] |
Assign pharmacological categories from List_of_CNS-active_medicines |
MDElliottMD (talk | contribs) parser-claude: Rizatriptan MedTemplate refill, Top 300 stub upgrade |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
{{MedTemplate | {{MedTemplate | ||
| generic | | generic = Rizatriptan (benzoate) | ||
| brand | | brand = Maxalt (tablet), Maxalt-MLT (orally disintegrating tablet) | ||
| structure | | structure = | ||
| classes | | classes = [[:Category:Triptans|Triptan (5-HT1B/1D agonist)]], [[:Category:Antimigraine medicines|Antimigraine medicine]], [[:Category:Analgesics|Analgesic]] | ||
| uses = <vote slug="acute-migraine-use">Acute migraine with or without aura (FDA; adult and pediatric ages 6+)</vote> | |||
| uses | | starting_dose = 5-10 mg PO at migraine onset; may repeat after 2 hours, maximum 30 mg/24 hours | ||
| starting_dose | | preparations = Tablets 5, 10 mg; ODT (Maxalt-MLT) 5, 10 mg | ||
| preparations | | fda_max = 30 mg/24 hours | ||
| fda_max = | | pill_id = | ||
| routes | | routes = Oral | ||
| onset | | onset = 30 minutes for migraine relief | ||
| duration | | duration = 4-6 hours; headache recurrence is common | ||
| halflife | | halflife = 2-3 hours<ref name="maxalt-label">FDA Prescribing Information, Maxalt (rizatriptan benzoate), Merck, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020864s022,020865s024lbl.pdf</ref> | ||
| bioavailability = ~45% (oral; substantially higher than sumatriptan's ~14%)<ref name="maxalt-label" /> | |||
| pregnancy = Limited human data; pregnancy registry data have been broadly reassuring across the triptan class.{{citation needed}} | |||
| legal = [[USLegal:Prescription only|Rx-only]] in US | |||
| | | mechanism = <vote slug="rizatriptan-mech-claim">Selective 5-HT1B and 5-HT1D receptor agonist (the triptan-class signature). Compared to sumatriptan, oral bioavailability is substantially higher (~45% vs ~14%) and onset is faster, with similar headache-recurrence rates. The 5-HT1B effect produces cranial vasoconstriction reversing the neurogenic vasodilation of migraine; the 5-HT1D effect inhibits CGRP release at trigeminal nerve terminals.</vote> '''Propranolol substantially raises rizatriptan exposure''' (~70% increase) via MAO-A inhibition of rizatriptan metabolism; the 5 mg dose is required when used with propranolol. Same triptan-class contraindications: coronary artery disease, vasospastic angina, uncontrolled hypertension, ischemic stroke history, hemiplegic or basilar migraine<ref name="maxalt-label" />. | ||
| | |||
| | |||
| | |||
| | |||
}} | }} | ||
== References == | |||
<references /> | |||
[[Category: | [[Category:Triptans]] | ||
[[Category: | [[Category:Antimigraine medicines]] | ||
[[Category:Analgesics]] | [[Category:Analgesics]] | ||